van Winden TMS, Roos C, Nijman TAJ, et al. - Researchers sought to compare tocolysis with no tocolysis in women with threatened preterm birth and ruptured membranes via assessment of combined data from the APOSTEL III RCT and the National Maternity Hospital, Dublin. In the APOSTEL III trial, either atosiban or nifedipine was provided to women with threatened preterm birth. They retrieved patient data from Ireland from a cohort of women with threatened preterm birth with ruptured membranes. No tocolytic treatment was received by the Irish women. Performing propensity score matching comparable groups were created. A total of 153 women from the Apostel III trial were compared with 51 eligible women from the Irish cohort. Findings revealed no alteration in composite adverse neonatal outcome or time to delivery in correlation with receiving tocolytic therapy among women with threatened preterm birth and ruptured membranes.